Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma

BACKGROUND: Diffusion-weighted imaging has shown initial promise for evaluating response to bevacizumab in patients with high-grade glioma (HGG). However, it is well recognized that the apparent diffusion coefficient (ADC) is influenced by bevacizumab-induced reductions in edema, which may limit its...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: McDonald, Carrie R., Delfanti, Rachel L., Krishnan, Anitha P., Leyden, Kelly M., Hattangadi-Gluth, Jona A., Seibert, Tyler M., Karunamuni, Roshan, Elbe, Pia, Kuperman, Joshua M., Bartsch, Hauke, Piccioni, David E., White, Nathan S., Dale, Anders M., Farid, Nikdokht
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2016
Sujets:
Clinical Investigation
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5063514/
https://ncbi.nlm.nih.gov/pubmed/27106406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now063
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires